Login
Evidence Feed
About
Diagnostics
New
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
MSI-H/dMMR + MLH1 deletion + PMS2 deletion
i
Other names:
MSI | Microsatellite instability, MLH1, COCA2, FCC2, HNPCC, HNPCC2, MutL homolog 1, PMS2, PMS1 Homolog 2, Mismatch Repair System Component, PMS1 Homolog 2, Mismatch Repair Protein, Mismatch Repair Endonuclease PMS2, DNA Mismatch Repair Protein PMS2, PMS1 Protein Homolog 2, PMSL2, PMS2 Postmeiotic Segregation Increased 2, Postmeiotic Segregation Increased 2 Nirs Variant 6, PMS2 Postmeiotic Segregation Increased 2, HNPCC4, PMS2CL, MLH4
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
4292
;
5395
Related biomarkers:
Expression
Mutation
CNA
Others
‹
CEACAM5 underexpression + MSI-H/dMMR (2)
MSI-H/dMMR + CD74 overexpression (2)
MSI-H/dMMR + HLA-B overexpression (2)
MSI-H/dMMR + HLA-DPA1 overexpression (2)
MSI-H/dMMR + HLA-DPB1 overexpression (2)
MSI-H/dMMR + HLA-DQA1 overexpression (2)
MSI-H/dMMR + HLA-DQB1 overexpression (2)
MSI-H/dMMR + HLA-DRB1 overexpression (2)
PMS2 negative (1)
CEACAM5 underexpression + MSI-H/dMMR (2)
MSI-H/dMMR + CD74 overexpression (2)
MSI-H/dMMR + HLA-B overexpression (2)
MSI-H/dMMR + HLA-DPA1 overexpression (2)
MSI-H/dMMR + HLA-DPB1 overexpression (2)
MSI-H/dMMR + HLA-DQA1 overexpression (2)
MSI-H/dMMR + HLA-DQB1 overexpression (2)
MSI-H/dMMR + HLA-DRB1 overexpression (2)
PMS2 negative (1)
›
Associations
News
Trials
VERI cancer hierarchy
Reset Filters
MSI-H/dMMR + MLH1 deletion + PMS2 deletion
Colorectal Cancer
MSI-H/dMMR + MLH1 deletion + PMS2 deletion
Colorectal Cancer
Immunotherapy
Resistant: C3 – Early Trials
Immunotherapy
Resistant
:
C3
Immunotherapy
Resistant: C3 – Early Trials
Immunotherapy
Resistant
:
C3
MSI-H/dMMR + MLH1 deletion + PMS2 deletion
Esophageal Adenocarcinoma
MSI-H/dMMR + MLH1 deletion + PMS2 deletion
Esophageal Adenocarcinoma
pembrolizumab
Sensitive: C4 – Case Studies
pembrolizumab
Sensitive
:
C4
pembrolizumab
Sensitive: C4 – Case Studies
pembrolizumab
Sensitive
:
C4
MSI-H/dMMR + MLH1 deletion + PMS2 deletion
Colorectal Cancer
MSI-H/dMMR + MLH1 deletion + PMS2 deletion
Colorectal Cancer
pembrolizumab
Sensitive: C4 – Case Studies
pembrolizumab
Sensitive
:
C4
pembrolizumab
Sensitive: C4 – Case Studies
pembrolizumab
Sensitive
:
C4
^
^
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.